Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Almirall S.A
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Almirall S.A.
- Almirall LLC
- Aqua Pharmaceuticals
- Taurus Pharma GmbH
- Polichem S.A.
- Polichem S.r.l.